| Title |
Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics
|
|---|---|
| Published in |
Archives of Pharmacal Research, May 2012
|
| DOI | 10.1007/s12272-012-0403-5 |
| Pubmed ID | |
| Authors |
Do-Hee Kim, Taebo Sim |
| Abstract |
Aberrant activation of Raf signaling pathway is frequently found in various human tumors, it has been considered as distinct and promising molecular target for cancer therapeutics. B-Raf is most attractive drug target out of three Raf isoforms (A-Raf, B-Raf and C-Raf) because it exhibits high kinase activity due to frequent mutations in human tumors. However, most recently, it has been reported that Raf isoforms show the cross-activation in the presence of specific B-Raf inhibitors, which brings about the paradoxical p-ERK activation as well as tumor promoting effect. According to these findings, it remains controversy whether pan-Raf kinase inhibitor is more valuable and promising rather than specific B-Raf inhibitor under certain conditions in terms of cancer therapeutics. In this short review, novel Raf kinase inhibitors undergoing clinical investigation are introduced. Moreover, the paradoxical p-ERK activation is discussed with specific B-Raf inhibitors, PLX4032/4720 compounds. |
Mendeley readers
The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 5% |
| Unknown | 19 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 25% |
| Student > Master | 5 | 25% |
| Researcher | 4 | 20% |
| Student > Bachelor | 3 | 15% |
| Unknown | 3 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 5 | 25% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 20% |
| Chemistry | 3 | 15% |
| Biochemistry, Genetics and Molecular Biology | 2 | 10% |
| Medicine and Dentistry | 2 | 10% |
| Other | 1 | 5% |
| Unknown | 3 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 February 2024.
All research outputs
#2,459,441
of 22,785,242 outputs
Outputs from Archives of Pharmacal Research
#46
of 1,294 outputs
Outputs of similar age
#16,240
of 163,664 outputs
Outputs of similar age from Archives of Pharmacal Research
#1
of 24 outputs
Altmetric has tracked 22,785,242 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,294 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 163,664 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.